The combination of cilengitide with trastuzumab produced a synergistic effect, leading to the most significant reduction in migration markers, indicating that dual targeting of HER2 and ITGB3 could be an effective strategy to limit metastasis in Trastuzumab-resistant HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.